ICICI Securities maintains a Buy call on Akums Drugs & Pharmaceuticals, setting a target price of Rs 710. The company reported a consolidated total income of Rs 1073.09 crore for the quarter ended March 31, 2025, reflecting year-over-year growth. Akums is expected to demonstrate strong revenue, EBITDA, and PAT CAGR growth over the next few years.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets